Author

Xinchun Tong

Observed names: Tong, Xinchun, X TONG, X. S. Tong, X. Tong, Xin-Chun Tong, Xinchun S Tong, Xinchun S. Tong, Xinchun. Tong

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), University of Wisconsin–Madison, Cornell University

OpenAlex ID: A5110048208

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

2006 · X TONG, R CHASE, et al. · Antiviral Research · 237

Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia

2011 · Wu Yin, Ester Carballo-Jane, et al. · Journal of Lipid Research · 218

PDF

Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice

2003 · L. P. Shearman, K. M. Rosko, et al. · Behavioural Pharmacology · 186

Chiral Separation and Detection of Terbutaline and Ephedrine by Capillary Electrophoresis Coupled with Ion Spray Mass Spectrometry

1995 · Robin L. Sheppard, Xinchun. Tong, et al. · Analytical Chemistry · 134

Characterization of resistance mutations against HCV ketoamide protease inhibitors

2008 · X TONG, S BOGEN, et al. · Antiviral Research · 127

Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

2006 · Linus S. Lin, Thomas J. Lanza,, et al. · Journal of Medicinal Chemistry · 123

Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents

2007 · Tung M. Fong, Xiao-Ming Guan, et al. · Journal of Pharmacology and Experimental Therapeutics · 103

Discovery of a Novel Glucagon Receptor AntagonistN-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes

2012 · Yusheng Xiong, Jian Guo, et al. · Journal of Medicinal Chemistry · 87

Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats

2009 · Hong C. Shen, Fa-Xiang Ding, et al. · Journal of Medicinal Chemistry · 82

PDF

Correolide and Derivatives Are Novel Immunosuppressants Blocking the Lymphocyte Kv1.3 Potassium Channels

1999 · Gloria C. Koo, Joseph T. Blake, et al. · Cellular Immunology · 81

Effect of Signal Interference from Dosing Excipients on Pharmacokinetic Screening of Drug Candidates by Liquid Chromatography/Mass Spectrometry

2002 · Xinchun S. Tong, Junying Wang, et al. · Analytical Chemistry · 76

Solid-phase method for the purification of DNA sequencing reactions

1992 · Xinchun. Tong, Lloyd. Smith · Analytical Chemistry · 74

Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib

2011 · Cameron J. Smith, Amjad Ali, et al. · Journal of Medicinal Chemistry · 70

1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

2012 · Petr Vachal, Shouwu Miao, et al. · Journal of Medicinal Chemistry · 67

Kinetic Monitoring of Enzymatic Reactions in Real Time by Quantitative High-Performance Liquid Chromatography-Mass Spectrometry

1995 · F.Y.L. Hsieh, X. Tong, et al. · Analytical Biochemistry · 61

Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

2016 · John S. Debenham, Christina Madsen-Duggan, et al. · Journal of Medicinal Chemistry · 56

Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

2005 · Christopher W. Plummer, Paul E. Finke, et al. · Bioorganic & Medicinal Chemistry Letters · 56

Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate

2010 · Hong C. Shen, Fa-Xiang Ding, et al. · Journal of Medicinal Chemistry · 55

Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity

2010 · Changyou Zhou, Margareta Garcia-Calvo, et al. · Journal of Medicinal Chemistry · 51

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core

2010 · Dong-Ming Shen, Edward J. Brady, et al. · Bioorganic & Medicinal Chemistry Letters · 47

Discovery of a Highly Potent, Selective, and Bioavailable Soluble Epoxide Hydrolase Inhibitor with Excellent Ex Vivo Target Engagement

2009 · Hong C. Shen, Fa-Xiang Ding, et al. · Journal of Medicinal Chemistry · 44

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors

2009 · Hong C. Shen, Fa-Xiang Ding, et al. · Bioorganic & Medicinal Chemistry Letters · 42

Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor

2008 · Richard Z. Chen, Andrea Frassetto, et al. · European Journal of Pharmacology · 41

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists

2005 · Dong-Ming Shen, Fengqi Zhang, et al. · Bioorganic & Medicinal Chemistry Letters · 40

Discovery of Biaryl Anthranilides as Full Agonists for the High Affinity Niacin Receptor

2007 · Hong C. Shen, Fa-Xiang Ding, et al. · Journal of Medicinal Chemistry · 37

Works count: 90

Citation count: 3,227

H-index: 31

I10-index: 76